Between 2003 and 2005, big pharma companies placed 52% more new drugs into clinical trials per year than in the prior five-year period, according to a study by the Tufts Center for the Study of Drug Development (CSDD). The CSDD included only new entities in clinical trials since 1993 (generics, new formulations of old drugs, or new indications for existing drugs were excluded), as determined according to total drug sales in 2004. The study addressed corporate merger activity by adding data from companies that had been acquired in the meantime.

The study authors divided the data set from the 13 years into one three-year set and two five-year sets for efficiency, says Joseph DiMasi, director of economic analysis at CSDD and leader of the study. Analysis was not performed to break out "me too" drugs.

The study also showed that one in four new compounds that entered into the clinic...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!